MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceGlobeNewsWire · Oct 14, 2026
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development OfficerGlobeNewsWire · Sep 23, 2026
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 11, 2026
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapiesGlobeNewsWire · Aug 19, 2026
MaxCyte Q2 Earnings Call HighlightsMarketBeat · Aug 12, 2026
MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 12, 2026MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.09 | -$0.08 | Beat |
| May 12, 2026 | -$0.10 | -$0.04 | Beat |
| Mar 24, 2026 | -$0.08 | -$0.06 | Beat |
| Nov 12, 2025 | -$0.11 | -$0.12 | Miss |
| Aug 6, 2025 | -$0.10 | -$0.12 | Miss |
| May 7, 2025 | -$0.10 | -$0.10 | Beat |